Literature DB >> 34296393

Histone Mark Profiling in Pediatric Astrocytomas Reveals Prognostic Significance of H3K9 Trimethylation and Histone Methyltransferase SUV39H1.

Alexia Klonou1, Penelope Korkolopoulou2, Antonios N Gargalionis1, Dimitrios S Kanakoglou2, Hector Katifelis3, Maria Gazouli3, Sarantis Chlamydas1, Andreas Mitsios4, Theodosis Kalamatianos5, George Stranjalis5, Marios S Themistocleous4, Kostas A Papavassiliou1, Spyros Sgouros6, Athanasios G Papavassiliou7, Christina Piperi8.   

Abstract

Alterations in global histone methylation regulate gene expression and participate in cancer onset and progression. The profile of histone methylation marks in pediatric astrocytomas is currently understudied with limited data on their distribution among grades. The global expression patterns of repressive histone marks H3K9me3, H3K27me3, and H4K20me3 and active H3K4me3 and H3K36me3 along with their writers SUV39H1, SETDB1, EZH2, MLL2, and SETD2 were investigated in 46 pediatric astrocytomas and normal brain tissues. Associations between histone marks and modifying enzymes with clinicopathological characteristics and disease-specific survival were studied along with their functional impact in proliferation and migration of pediatric astrocytoma cell lines using selective inhibitors in vitro. Upregulation of histone methyltransferase gene expression and deregulation of histone code were detected in astrocytomas compared to normal brain tissues, with higher levels of SUV39H1, SETDB1, and SETD2 as well as H4K20me3 and H3K4me3 histone marks. Pilocytic astrocytomas exhibited lower MLL2 levels compared to diffusely infiltrating tumors indicating a differential pattern of epigenetic regulator expression between the two types of astrocytic neoplasms. Moreover, higher H3K9me3, H3K36me3, and SETDB1 expression was detected in grade IIΙ/IV compared to grade II astrocytomas. In univariate analysis, elevated H3K9me3 and MLL2 and diminished SUV39H1 expression adversely affected survival. Upon multivariate survival analysis, only SUV39H1 expression was revealed as an independent prognostic factor of adverse significance. Treatment of pediatric astrocytoma cell lines with SUV39H1 inhibitor reduced proliferation and cell migration. Our data implicate H3K9me3 and SUV39H1 in the pathobiology of pediatric astrocytomas, with SUV39H1 yielding prognostic information independent of other clinicopathologic variables.
© 2021. The American Society for Experimental NeuroTherapeutics, Inc.

Entities:  

Keywords:  H3K9me3; Histone methylation; Pediatric astrocytomas; SUV39H1; Survival

Mesh:

Substances:

Year:  2021        PMID: 34296393      PMCID: PMC8609021          DOI: 10.1007/s13311-021-01090-x

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   6.088


  43 in total

1.  H3K4/H3K9me3 Bivalent Chromatin Domains Targeted by Lineage-Specific DNA Methylation Pauses Adipocyte Differentiation.

Authors:  Yoshihiro Matsumura; Ryo Nakaki; Takeshi Inagaki; Ayano Yoshida; Yuka Kano; Hiroshi Kimura; Toshiya Tanaka; Shuichi Tsutsumi; Mitsuyoshi Nakao; Takefumi Doi; Kiyoko Fukami; Timothy F Osborne; Tatsuhiko Kodama; Hiroyuki Aburatani; Juro Sakai
Journal:  Mol Cell       Date:  2015-11-19       Impact factor: 17.970

Review 2.  Orchestrating high-throughput genomic analysis with Bioconductor.

Authors:  Wolfgang Huber; Vincent J Carey; Robert Gentleman; Simon Anders; Marc Carlson; Benilton S Carvalho; Hector Corrada Bravo; Sean Davis; Laurent Gatto; Thomas Girke; Raphael Gottardo; Florian Hahne; Kasper D Hansen; Rafael A Irizarry; Michael Lawrence; Michael I Love; James MacDonald; Valerie Obenchain; Andrzej K Oleś; Hervé Pagès; Alejandro Reyes; Paul Shannon; Gordon K Smyth; Dan Tenenbaum; Levi Waldron; Martin Morgan
Journal:  Nat Methods       Date:  2015-02       Impact factor: 28.547

Review 3.  Updates in Pediatric Malignant Gliomas.

Authors:  Fabrício Guimarães Gonçalves; César Augusto Pinheiro Ferreira Alves; Arastoo Vossough
Journal:  Top Magn Reson Imaging       Date:  2020-04

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  The HP1alpha-CAF1-SetDB1-containing complex provides H3K9me1 for Suv39-mediated K9me3 in pericentric heterochromatin.

Authors:  Alejandra Loyola; Hideaki Tagami; Tiziana Bonaldi; Danièle Roche; Jean Pierre Quivy; Axel Imhof; Yoshihiro Nakatani; Sharon Y R Dent; Geneviève Almouzni
Journal:  EMBO Rep       Date:  2009-06-05       Impact factor: 8.807

Review 6.  H3K9me3-Dependent Heterochromatin: Barrier to Cell Fate Changes.

Authors:  Justin S Becker; Dario Nicetto; Kenneth S Zaret
Journal:  Trends Genet       Date:  2015-12-08       Impact factor: 11.639

7.  Malignant Gliomas as Second Neoplasms in Pediatric Cancer Survivors: Neuropathological Study.

Authors:  Ewa Izycka-Swieszewska; Ewa Bien; Joanna Stefanowicz; Edyta Szurowska; Ewa Szutowicz-Zielinska; Magdalena Koczkowska; Dawid Sigorski; Wojciech Kloc; Wojciech Rogowski; Elzbieta Adamkiewicz-Drozynska
Journal:  Biomed Res Int       Date:  2018-04-01       Impact factor: 3.411

8.  An end to end workflow for differential gene expression using Affymetrix microarrays.

Authors:  Bernd Klaus; Stefanie Reisenauer
Journal:  F1000Res       Date:  2016-06-15

9.  Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.

Authors:  Chul-Hwan Lee; Jia-Ray Yu; Jeffrey Granat; Ricardo Saldaña-Meyer; Joshua Andrade; Gary LeRoy; Ying Jin; Peder Lund; James M Stafford; Benjamin A Garcia; Beatrix Ueberheide; Danny Reinberg
Journal:  Genes Dev       Date:  2019-09-05       Impact factor: 11.361

10.  Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.

Authors:  Tina Huang; Roxanna Garcia; Jin Qi; Rishi Lulla; Craig Horbinski; Amir Behdad; Nitin Wadhwani; Ali Shilatifard; Charles James; Amanda M Saratsis
Journal:  Oncotarget       Date:  2018-12-14
View more
  1 in total

1.  Laying the groundwork for the Biobank of Rare Malignant Neoplasms at the service of the Hellenic Network of Precision Medicine on Cancer.

Authors:  Dimitrios S Kanakoglou; Andromachi Pampalou; Dimitrios M Vrachnos; Eleni A Karatrasoglou; Dionysia N Zouki; Emmanouil Dimonitsas; Alexia Klonou; Georgia Kokla; Varvara Theologi; Errieta Christofidou; Stratigoula Sakellariou; Eleftheria Lakiotaki; Christina Piperi; Penelope Korkolopoulou
Journal:  Int J Oncol       Date:  2022-02-16       Impact factor: 5.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.